fbpx

Onconetix Inc

ONCO

$0.65

Closing

▲5.70%

1D

▼-91.83%

YTD

ONCO

BBG00PNSYQK0

Exchange

Sector

Market cap

$5.37M

Volume

12,871

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$5.37M

Analysts' Rating

-

Price Target (Mean)

0.00

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

Revenue Growth

0.00%

52 week high

$21.28

52 week low

$0.60

Div. Yield

%

EPS Growth

0.00

Company Profile

Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.